PROTAC Targeted Protein Degrader Clinical Trial Landscape

What are PROTACs and targeted protein degraders?

A PROTAC (PROteolysis TArgeting Chimera) is a bifunctional small molecule that induces targeted degradation of a specific disease-causing protein. Rather than blocking a protein's activity like traditional inhibitors, PROTACs recruit an E3 ubiquitin ligase to the target protein — causing it to be tagged for destruction by the cell's proteasome machinery. The target protein is eliminated, not just inhibited.

The PROTAC concept was first described by Craig Crews and colleagues at Yale in 2001. It took two decades of medicinal chemistry advances before the first PROTAC candidates reached human clinical trials, with the first Phase 1 studies opening around 2019-2021. By 2024, vepdegestrant (ARV-471) became the first PROTAC to enter Phase 3 — a milestone for the entire field.

The broader category of "targeted protein degraders" includes:

• PROTACs — bifunctional molecules with separate E3 ligase-recruiting and target-binding warheads connected by a linker
• Molecular glues — small molecules that directly stabilize protein-protein interactions between a target and an E3 ligase (lenalidomide, pomalidomide, mezigdomide are molecular glues of cereblon)
• Lysosome-targeting chimeras (LYTACs) — use lysosomal degradation pathways instead of the proteasome; can target extracellular and membrane proteins
• Autophagy-targeting chimeras (AUTACs) — route targets to autophagosomes for degradation

Lead PROTAC programs in active clinical trials

Vepdegestrant (ARV-471) — Estrogen Receptor PROTAC

Developer: Arvinas / Pfizer  |  Target: Estrogen receptor (ER / ESR1)  |  Indication: ER+/HER2- metastatic breast cancer

Vepdegestrant is the most advanced PROTAC in clinical development and the first to reach Phase 3. It degrades ERα by recruiting the CRBN E3 ligase complex. The key advantage over selective estrogen receptor degraders (SERDs) like fulvestrant is its oral bioavailability and potency against ESR1-mutant tumors — the primary resistance mechanism to aromatase inhibitors. Pfizer licensed rights to vepdegestrant from Arvinas in 2021 in a deal worth up to $1.4 billion, one of the largest PROTAC deals to date.

BGB-16673 — BTK PROTAC

Developer: BeiGene  |  Target: Bruton's tyrosine kinase (BTK)  |  Indication: CLL, SLL, MCL, Waldenström's macroglobulinemia

BGB-16673 is a BTK-targeting PROTAC designed to overcome resistance to covalent BTK inhibitors (ibrutinib, zanubrutinib, acalabrutinib). The most common resistance mechanism to covalent BTK inhibitors is a C481S mutation at the covalent binding site. Because BGB-16673 degrades BTK rather than covalently inhibiting it, C481S mutations do not confer resistance — the degrader can bind BTK at a non-covalent site and still recruit an E3 ligase. BeiGene now has three Phase 3 trials of BGB-16673 recruiting in CLL and MCL, representing a major strategic bet that BTK degradation is the next standard of care in B-cell malignancies.

CFT7455 — IKZF1/IKZF3 Molecular Glue Degrader

Developer: C4 Therapeutics  |  Target: IKZF1 (Ikaros) and IKZF3 (Aiolos)  |  Indication: Multiple myeloma, non-Hodgkin lymphoma

CFT7455 is a next-generation molecular glue degrader of IKZF1 and IKZF3 — the same neo-substrates targeted by lenalidomide and pomalidomide, but with substantially greater potency. In preclinical studies, CFT7455 showed activity in lenalidomide/pomalidomide-resistant models, which is critical as more myeloma patients exhaust IMiD-class options. CFT7455 represents the molecular glue approach to protein degradation — it directly stabilizes the CRBN-IKZF1/3 interaction rather than using a separate linker-target binding domain like a PROTAC.

CC-94676 — Androgen Receptor Molecular Glue Degrader

Developer: Celgene / Bristol-Myers Squibb  |  Target: Androgen receptor (AR)  |  Indication: Metastatic castration-resistant prostate cancer

CC-94676 is BMS's AR-targeting degrader — designed to address resistance to androgen receptor signaling inhibitors (ARSIs) like enzalutamide and abiraterone in prostate cancer. AR amplification and mutation are the dominant resistance mechanisms to these agents. By degrading AR protein rather than blocking its binding pocket, CC-94676 aims to be effective even when AR is overexpressed or mutated.

Why PROTACs matter for competitive intelligence

Every major pharma now has a degrader program

As of 2026, virtually every major pharmaceutical company has invested in targeted protein degradation. The key signals to monitor: (1) new IND filings and Phase 1 trial registrations — these give the earliest public indication of a company's PROTAC strategy; (2) Phase 2 data readouts — dose-finding in Phase 1/2 studies directly informs Phase 3 design; (3) combination trial starts — most degraders will be used in combination, and the combinations chosen reveal strategic partnerships and competitive positioning.

The resistance narrative drives valuation

The bull case for PROTACs is explicitly built on resistance to existing therapies. Ibrutinib resistance (C481S) validated BTK PROTACs. ESR1 mutation validated ER PROTACs. AR amplification validated AR degraders. As each resistance mechanism becomes clinically significant, it creates a new market for a degrader — making PROTAC program monitoring directly relevant to understanding which late-line therapy markets will develop over a 3-7 year horizon.

Target diversity is expanding rapidly

Beyond BTK, ER, and AR, PROTAC programs in early-stage trials or preclinical development now cover: BRD4 (transcription), SMARCA2/SMARCA4 (SWI/SNF chromatin remodeling), BCL-XL (apoptosis evasion), CDK9 (transcription-dependent cancer), STAT3, KRAS, and others. Each new target represents a potential Phase 1 trial filing. DataLookout tracks these registrations daily.

Who monitors PROTAC clinical trials

Pharma business development teams

BD teams at companies with PROTAC or small-molecule oncology programs track competitor degrader trials to identify acquisition targets, partnership opportunities, and competitive threats. A Phase 1 BTK degrader trial at a small biotech could be a licensing opportunity — or signal that a competitor is moving into your space.

Biotech investors and analysts

Degrader-focused investors track Phase 1 trial openings as early indicators of clinical validation. Phase 3 milestones (like vepdegestrant's VERITAC-3 launch) are material catalysts. Monitoring trial status changes — particularly enrollment completion and primary completion date updates — gives leading indicators of data readout timelines.

CROs specializing in oncology

Contract research organizations with oncology practices track new degrader trial registrations to identify sponsors entering clinical development — prospective clients who will need Phase 1 site selection, PK/PD assay development, and biomarker monitoring services specialized to this modality.

Frequently asked questions